1. Home
  2. APVO vs CETX Comparison

APVO vs CETX Comparison

Compare APVO & CETX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APVO
  • CETX
  • Stock Information
  • Founded
  • APVO 2016
  • CETX 1998
  • Country
  • APVO United States
  • CETX United States
  • Employees
  • APVO N/A
  • CETX N/A
  • Industry
  • APVO Biotechnology: Pharmaceutical Preparations
  • CETX EDP Services
  • Sector
  • APVO Health Care
  • CETX Technology
  • Exchange
  • APVO Nasdaq
  • CETX Nasdaq
  • Market Cap
  • APVO 4.9M
  • CETX 4.3M
  • IPO Year
  • APVO N/A
  • CETX 1998
  • Fundamental
  • Price
  • APVO $1.78
  • CETX $5.02
  • Analyst Decision
  • APVO
  • CETX
  • Analyst Count
  • APVO 0
  • CETX 0
  • Target Price
  • APVO N/A
  • CETX N/A
  • AVG Volume (30 Days)
  • APVO 16.3M
  • CETX 139.1K
  • Earning Date
  • APVO 11-06-2025
  • CETX 08-14-2025
  • Dividend Yield
  • APVO N/A
  • CETX N/A
  • EPS Growth
  • APVO N/A
  • CETX N/A
  • EPS
  • APVO N/A
  • CETX N/A
  • Revenue
  • APVO N/A
  • CETX $76,095,551.00
  • Revenue This Year
  • APVO N/A
  • CETX $19.77
  • Revenue Next Year
  • APVO N/A
  • CETX $15.00
  • P/E Ratio
  • APVO N/A
  • CETX N/A
  • Revenue Growth
  • APVO N/A
  • CETX 16.50
  • 52 Week Low
  • APVO $1.32
  • CETX $4.81
  • 52 Week High
  • APVO $381.10
  • CETX $845.25
  • Technical
  • Relative Strength Index (RSI)
  • APVO 53.33
  • CETX 75.19
  • Support Level
  • APVO $1.41
  • CETX $5.03
  • Resistance Level
  • APVO $1.49
  • CETX $5.56
  • Average True Range (ATR)
  • APVO 0.18
  • CETX 0.36
  • MACD
  • APVO 0.04
  • CETX 0.44
  • Stochastic Oscillator
  • APVO 35.04
  • CETX 81.13

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

About CETX Cemtrex Inc.

Cemtrex Inc is a multi-industry technology company. It has expanded in a range of sectors, including smart technologies, virtual and augmented realities, industrial solutions, and intelligent security system. The company's operating segment includes, Security segment, Industrial Services segment and the corporate segment. The security segment provides end to end security to all industrial, corporate and governmental security via owned subsidiary Vicon. Whereas AIS part Industrial Service Segment is expertise services for rigging, millwrighting, in plant maintenance, equipment erection, relocation, and disassembly to diversified customers. It generates maximum revenue from the Industrial Service Segment. It geographically operates in USA, UK and India, with maximum of revenue from USA.

Share on Social Networks: